A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: The oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2)

G. Y.H. Lip, J. L. Halperin, P. Petersen, G. M. Rodgers, D. Pall, R. W. Renfurm

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: The oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2)'. Together they form a unique fingerprint.

Medicine & Life Sciences